Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands

References

• Rijksinstituut voor Volkgezondheid en Milieu. National Public Health Compass. How common is diabetes and how many people die from it? http://www.nationaalkompas.nl/gezondheid-en-ziekte/ziekten-en-aandoeningen/endocriene-voedings-en-stofwisselingsziekten-en-immuniteitsstoornissen/diabetes-mellitus/omvang/. Accessed September 1, 2015
   Google Scholar
• Ujcic-Voortman JK, Schram MT, Jacobs-van der Bruggen MA, et al. Diabetes prevalence and risk factors among ethnic minorities. Eur J Public Health 2009;19:511-15
   PubMed Web of Science ®Google Scholar
• Rutten GEHM, Janssen PGH. Screening for type 2 diabetes – The ADDITION Netherlands Study. Eur Endocrinol 2009;5:32-7
   Google Scholar
• van der Heijden AA, de Bruijne MC, Feenstra TL, et al. Resource use and costs of type 2 diabetes patients receiving managed or protocolized primary care: a controlled clinical trial. BMC Health Serv Res 2014;14:280
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al., Management of hyperglycaemia in type 2 diabetes 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6
   PubMed Web of Science ®Google Scholar
• Reznik Y, Cohen O, Aronson R, et al; OpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 2014;384:1265-72
   PubMed Web of Science ®Google Scholar
• Aronson R, Reznik Y, Conget I, et al; OpT2mise Study Group. Sustained efficacy of insulin pump therapy, compared with multiple daily injections, in type 2 diabetes: 12-month data from the OpT2mise randomized trial. Diabetes Obes Metab 2016 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Noh YH, Lee SM, Kim EJ, et al. Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion. Diabetes Metab Res Rev 2008;24:384-91
   PubMed Web of Science ®Google Scholar
• Berthe E, Lireux B, Coffin C, et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res 2007;39:224-9
   PubMed Web of Science ®Google Scholar
• Wainstein J, Metzger M, Boaz M, et al. Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diabet Med 2005;22:1037-46
   PubMed Web of Science ®Google Scholar
• Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003;26:2598-603
   PubMed Web of Science ®Google Scholar
• Bode BW. Insulin pump use in type 2 diabetes. Diabetes Technol Ther 2010;12(1 Suppl):S17-S21
   Google Scholar
• St Charles ME, Sadri H, Minshall ME, et al. Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. Clin Ther 2009;31:657-67
   PubMed Web of Science ®Google Scholar
• St Charles M, Lynch P, Graham C, et al. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. Value Health 2009;12:674-86
   PubMed Web of Science ®Google Scholar
• Cohen N, Minshall ME, Sharon-Nash L, et al. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Pharmacoeconomics 2007;25:881-97
   PubMed Web of Science ®Google Scholar
• Conget Donlo I, Serrano Contreras D, Rodríguez Barrios JM, et al. [Cost-utility analysis of insulin pumps compared to multiple daily doses of insulin in patients with type 1 diabetes mellitus in Spain]. Rev Esp Salud Publica 2006;80:679-95
   PubMed Web of Science ®Google Scholar
• Roze S, Valentine WJ, Zakrzewska KE, et al. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabet Med 2005;22:1239-45
   PubMed Web of Science ®Google Scholar
• Roze S, Smith-Palmer J, Valentine W, et al. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review. Diabet Med 2015;32:1415-24
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-S26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(1 Suppl):S27-S40
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE Diabetes Model. Value Health 2014;17:714-24
   PubMed Web of Science ®Google Scholar
• de Vries FM, Denig P, Visser ST, et al. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands. Value Health 2014;17:223-30
   PubMed Web of Science ®Google Scholar
• Eefting F, Nathoe H, van Dijk D, et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. Circulation 2003;108:2870-6
   PubMed Web of Science ®Google Scholar
• Nederlands Huisarten Genootschap. Utrecht, The Netherlands. https://www.nhg.org/. Accessed July 2, 2015
   Google Scholar
• Nederlandse Zorgautoriteit. Tarieven en prestaties. Utrecht, The Netherlands. http://www.nza.nl/regelgeving/tarieven/. Accessed July 2, 2015
   Google Scholar
• Redekop WK, McDonnell J, Verboom P, et al. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics 2003;21:1171-83
   PubMed Web of Science ®Google Scholar
• Sørensen J, Ploug UJ. The cost of diabetes-related complications: registry-based analysis of days absent from work. Econ Res Int 2013;2013:1-8
   Google Scholar
• Beaudet A, Clegg J, Thuresson PO, et al. Review of utility values for economic modeling in type 2 diabetes. Value Health 2014;17:462-70
   PubMed Web of Science ®Google Scholar
• College voor zorgverzekeringen. Guidelines for pharmacoeconomic research, updated version College voor zorgverzekeringen. 2006. http://www.ispor.org/peguidelines/source/HTAGuidelinesNLupdated2006.pdf. Accessed May 21, 2015
   Google Scholar
• RVZ. Zinnige en duurzame zorg (Sensible and sustainable Care). Zoetermeer. Raad voor de Volksgezondheid en Zorg (Council for Public Health and Health Care); 2006. Report nr. 06/06
   Google Scholar
• RVZ. Rechtvaardige en duurzame zorg (Justified and sustainable care). Den Haag. Raad voor de Volksgezondheid en Zorg (Council for Public Health and Health Care); 2007. Report nr. 07/04. ISBN 978-90-5732-183-2
   Google Scholar
• Zorginstituut Nederland. Rapport kosteneffectiviteit in de praktijk. https://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/rapporten-en-standpunten/2015/1506-kosteneffectiviteit-in-de-praktijk/1506-kosteneffectiviteit-in-de-praktijk/Kosteneffectiviteit+in+de+praktijk.pdf. Accessed 7 October, 2015
   Google Scholar
• Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005;28:1568-73
   PubMed Web of Science ®Google Scholar
• Reznik Y, Morera J, Rod A, et al. Efficacy of continuous subcutaneous insulin infusion in type 2 diabetes mellitus: a survey on a cohort of 102 patients with prolonged follow-up. Diabetes Technol Ther 2010;12:931-6
   PubMed Web of Science ®Google Scholar
• Landman GW, van Hateren KJ, Kleefstra N, et al. The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11). Br J Gen Pract 2010;60:172-5
   PubMed Web of Science ®Google Scholar
• Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 2010;268:471-82
   PubMed Web of Science ®Google Scholar
• United States Centers for Disease Control and Prevention. Diabetes Public Health Resource. Percentage with A1c >9% among adults with diagnosed diabetes, by age, United States, 1988–1994 to 1999–2006. http://www.cdc.gov/diabetes/statistics/a1c/a1c_pct3_by_agegrp.htm. Accessed May 29, 2015
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes 2015. Diabetes Care 2015:38(1 Suppl):S1-S99
   PubMedGoogle Scholar
• Lassmann-Vague V, Clavel S, Guerci B, et al; Société francophone du diabète (ex ALFEDIAM). When to treat a diabetic patient using an external insulin pump. Expert consensus. Société francophone du diabète (ex ALFEDIAM) 2009. Diabetes Metab 2010;36:79-85
   PubMed Web of Science ®Google Scholar
• German Diabetes Association, Matthaei S, Bierwirth R, et al. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 2009;117:522-57
   PubMed Web of Science ®Google Scholar
• Grunberger G, Abelseth JM, Bailey TS, et al. Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force. Endocr Pract 2014;20:463-89
   Web of Science ®Google Scholar
• Guzmán JR, Lyra R, Aguilar-Salinas CA, et al; ALAD Consensus Group. Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association. Rev Panam Salud Publica 2010;28:463-71
   PubMed Web of Science ®Google Scholar
• David G, Shafiroff J, Saulnier A, et al. Multiple daily injection therapy (MDI) versus durable insulin pump therapy in type II diabetics: a breakeven analysis. Value Health 2012;15:A65
   Google Scholar
• David G, Gill M, Gunnarsson C, et al. Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetes. Am J Manag Care 2014;20:e490-7
   PubMed Web of Science ®Google Scholar